Company Analysis
Sign in

Spruce Biosciences, Inc. (SPRB)

Nasdaq: SPRB · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2020
Full chart Alerts Compare
Grade4.2
◀ Past 2.3● Present 4.5▶ Future 5.1
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

10 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Spruce Biosciences, Inc.’s names, not what it holds today.

Patents granted
10
10 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 3 in 2024 and 1 in 2023
Applications published
25
5 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals8
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Spruce Biosciences, Inc. its own name
named as the applicant on its applications, in US
0 granted
24 published
SPRUCE BIOSCIENCES, INC. its own name
US, as the owner printed on each patent
10 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 15, 202412,115,166Corticotropin releasing factor receptor antagonistsPharmaceuticalsSPRUCE BIOSCIENCES, INC.
Sep 24, 202412,098,152Methods and compositions for treating polycystic ovary syndromePharmaceuticalsSPRUCE BIOSCIENCES, INC.
Jan 2, 202411,858,932Methods and compositions for treating polycystic ovary syndromePharmaceuticalsSPRUCE BIOSCIENCES, INC.
Jul 25, 202311,708,372Crystalline composition of tildacerfont and methods of use and preparation thereofOrganic fine chemistrySPRUCE BIOSCIENCES, INC.
Jun 7, 202211,351,177Corticotropin releasing factor receptor antagonistsPharmaceuticalsSPRUCE BIOSCIENCES, INC.
May 31, 202211,344,557Corticotropin releasing factor receptor antagonistsPharmaceuticalsSPRUCE BIOSCIENCES, INC.
Apr 26, 202211,311,549Corticotropin releasing factor receptor antagonistsPharmaceuticalsSPRUCE BIOSCIENCES, INC.
Apr 19, 202211,304,950Methods for treating testicular and ovarian adrenal rest tumorsPharmaceuticalsSPRUCE BIOSCIENCES, INC.
May 18, 202111,007,201Corticotropin releasing factor receptor antagonistsPharmaceuticalsSPRUCE BIOSCIENCES, INC.
Dec 1, 202010,849,908Corticotropin releasing factor receptor antagonistsPharmaceuticalsSPRUCE BIOSCIENCES, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 26, 20252025/0206733METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROMEPharmaceuticalsSpruce Biosciences, Inc.
Jun 19, 20252025/0195527METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORSPharmaceuticalsSpruce Biosciences, Inc.
Jun 5, 20252025/0177404METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORSPharmaceuticalsSpruce Biosciences, Inc.
Jun 5, 20252025/0177403METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORSPharmaceuticalsSpruce Biosciences, Inc.
Feb 27, 20252025/0064812METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORSPharmaceuticalsSpruce Biosciences, Inc.
Sep 5, 20242024/0293421CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOFPharmaceuticalsSpruce Biosciences, Inc.
Aug 8, 20242024/0261300METHODS OF TREATING CONGENITAL ADRENAL HYPERPLASIAPharmaceuticalsSpruce Biosciences, Inc.
Feb 8, 20242024/0043432CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOFOrganic fine chemistrySpruce Biosciences, Inc.
Dec 28, 20232023/0414627CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTSPharmaceuticalsSpruce Biosciences, Inc. · patent 12,115,166 granted from it
Oct 12, 20232023/0322775METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROMEPharmaceuticalsSpruce Biosciences, Inc. · patent 11,858,932 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 7 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton SPRB · research, not advice